Skip to content
16 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · Pharma and healthcare · one day

AstraZeneca (AZN): news on Sunday 15 November 2026

News from the 24 hours to Sunday morning, 15 November 2026.

Tone of the day

+7.5strongly positive
Relevant headlines9of 14 read
Stories5grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage leaned positive on US approvals for two treatments and progress toward EU clearance for a hypertension drug. This was partly offset by reports of 600 US job cuts under a cost-saving plan, while AstraZeneca's SAP cloud deal drew mild positive mentions.

What drove it

  • FDA approvals
  • US job cuts
  • SAP cloud deal

Around this day

DayToneHeadlines
Mon 9 Nov+5.34
Tue 10 Nov+5.512
Wed 11 Nov+6.322
Thu 12 Nov+7.525
Fri 13 Nov+5.38
Sat 14 Nov+5.539
Sun 15 Nov+7.59
Mon 16 Nov+4.56

5 stories · 9 headlines · strongest first

Pharma and healthcare on 15 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
AstraZeneca signs cloud ERP deal with SAP +3.34 headlines today · Articles say AstraZeneca signed on to a large SAP cloud move, alongside a JPMorgan SAP target increase and SAP buyback.
+4.2AZ named as a client moving to SAP cloud; mainly an SAP story.AD HOC NEWS (opens the article) ↗
+4.2AZ commits to a large cloud migration; focus is on SAP.AD HOC NEWS (opens the article) ↗
+2.5AZ cloud deal mentioned, but story centres on SAP.AD HOC NEWS (opens the article) ↗
+2.5AZ cloud deal is a minor part of an SAP story.AD HOC NEWS (opens the article) ↗
AstraZeneca reduces its US sales workforce by 600 positions −2.72 headlines today · 16 in all, since 14 November · Reports cover the 600 US job cuts within a $1.5bn savings plan.
−3.3Job losses in the US, though part of a cost-saving programme.Analytics Insight (opens the article) ↗
−2.5Share-focused look at US sales reductions and cost drive.AD HOC NEWS (opens the article) ↗
FDA approves AstraZeneca's Klygefa for myasthenia gravis +10.01 headline today · The FDA approved Klygefa for generalised myasthenia gravis.
+10.0US regulator clears new treatment for a rare muscle condition.Dealroom (opens the article) ↗
FDA approves Imfinzi regimen for bladder cancer +10.01 headline today · 8 in all, since 14 November · Imfinzi combined with enfortumab vedotin has received FDA approval in cases of muscle-invasive bladder cancer.
+10.0US clearance widens use of Imfinzi in bladder cancer.Dealroom (opens the article) ↗
EU committee recommends AstraZeneca's Baxfendy for hypertension +8.91 headline today · 8 in all, since 14 November · Baxfendy, a hypertension treatment that is the first of its type, has taken a step towards authorisation in the EU.
+9.2Novel hypertension drug advancing toward European regulatory clearance.Indian Pharma Post (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 16 November · 220 headlines · 52 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt